The sourcing of pharmaceuticals for clinical trials is a critical decision that impacts the efficiency, cost, and overall success of the trial.
Companies often face the choice between central sourcing, where pharmaceutical products are obtained from a single supplier, and in-country sourcing, where products are procured within the country where the trial is conducted.
Both approaches have distinct advantages and disadvantages that must be carefully considered.
CentRal sourcing pharmaceutical products
The benefits of central sourcing
- Consistency and quality control: Central sourcing allows for standardised procedures and uniform quality control measures. This ensures all trial sites receive pharmaceuticals of consistent quality, which is crucial for maintaining the integrity of clinical trial results. Central suppliers often have stringent quality assurance protocols, reducing the risk of variability that could affect trial outcomes.
- Streamlined logistics: Managing a single central supplier simplifies the logistics of procurement, storage, and distribution. It reduces the complexity associated with coordinating multiple suppliers, each with their own delivery schedules and storage requirements. Central sourcing can lead to more predictable and reliable supply chains.
- Cost efficiency: Bulk purchasing from a central supplier can lead to cost savings through economies of scale. Negotiating large orders may result in discounts and lower per-unit costs. Additionally, centralised management can reduce administrative overhead and simplify inventory management.
- Regulatory compliance: Central suppliers are often experienced in navigating international regulations, ensuring that pharmaceuticals meet the necessary legal and safety standards across different trial locations. This can streamline the approval process and reduce the risk of regulatory non-compliance.
The disadvantages of central sourcing
- Longer lead times: Central sourcing, especially from international suppliers, can result in longer lead times due to shipping and customs clearance processes. Delays in supply can disrupt clinical trial schedules and increase the risk of stockouts.
- Dependency on a single supplier: Relying on a single central supplier can be risky if the supplier faces production issues, regulatory problems, or other disruptions. This dependency can jeopardise the continuity of the trial.
- Increased shipping costs: International shipping and handling can add significant costs and complexity, particularly for temperature-sensitive products that require specialised packaging and monitoring.
Cental sourcing pharmaceutical products
The benefits of in-country sourcing
- Faster supply chain: Sourcing pharmaceuticals within the trial country can significantly reduce lead times. Local suppliers can deliver products quickly, minimising the risk of delays and ensuring that trial sites remain adequately stocked.
- Lower shipping costs: Reduced shipping distances lower transportation costs and eliminate the need for complex import procedures. This can be particularly advantageous for budget-conscious trials.
- Regulatory familiarity: Local suppliers are well-versed in their country’s regulatory requirements, facilitating smoother compliance processes. This local expertise can help navigate country-specific regulations more efficiently.
- Enhanced flexibility: In-country sourcing allows for greater flexibility in responding to changing trial needs. If additional supplies are required unexpectedly, local suppliers can often accommodate these needs more rapidly than international sources.
The disadvantages of in-country sourcing
- Variable quality control: There can be variability between the quality control standards of respective In-country suppliers for multi-country trials, which can lead to inconsistencies in the pharmaceutical products provided. This variability can affect the reliability of trial results.
- Limited supplier options: Depending on the country, the availability of local suppliers meeting the required standards may be limited. This can restrict options and potentially lead to higher costs or compromises in quality.
- Coordination challenges: Managing multiple local suppliers can complicate logistics and increase administrative burdens. Coordinating different suppliers’ schedules and ensuring consistent quality across all sites can be challenging.
- Regulatory variability: While local suppliers are familiar with their own regulations, the variability in regulatory standards across different countries can complicate multi-country trials. Ensuring uniform compliance across all trial locations can be more difficult with multiple local suppliers.
Conclusion
The decision between central and in-country sourcing of pharmaceuticals for clinical trials depends on various factors, including the trial’s scale, budget, regulatory environment, and logistical considerations. Central sourcing offers consistency and cost-efficiency, while in-country sourcing provides speed and flexibility. Understanding the specific needs and constraints of the trial is essential for selecting the optimal sourcing strategy.
About AKESA
At Akesa, we specialise in both central and in-country sourcing, offering tailored solutions to meet the unique needs of each clinical trial. Our expertise ensures seamless supply chain management, enabling successful trial outcomes.
Contact us to learn more about how we can support your clinical research needs.
Image by LinkedIn Sales Solution on Unsplash.
